Daniel Chung swaps SparingVision for Beacon

US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung (pictured above) as chief medical officer (CMO).

Dr Chung brings a wealth of experience in clinical ophthalmology, academic research and gene therapy development spanning three decades. Most recently, he served as CMO at SparingVision, another genomic medicine company focused on the treatment of retinal disease. 

Previously, Dr Chung served as ophthalmology therapeutic area leader at Spark Therapeutics, where he played an instrumental role in the development of Luxturna (voretigene neparvovec), the first gene therapy approved by the US Food and Drug Administration and European Medicines Agency for use in a blinding genetic disease.